Drug dosage in children with reduced renal function

Pediatric Nephrology

Volumn 20, Issue 12, 2005, Pages 1675-1686

  Daschner, Markus ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Drug dosage; Neonates; Nephrology; Paediatrics; Renal failure

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANALGESIC AGENT; ANTHELMINTIC AGENT; ANTIALLERGIC AGENT; ANTIASTHMATIC AGENT; ANTICONVULSIVE AGENT; ANTIEMETIC AGENT; ANTIFUNGAL AGENT; ANTIGOUT AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFLAMMATORY AGENT; ANTIVIRUS AGENT; CENTRAL NERVOUS SYSTEM AGENTS; CEPHALOSPORIN DERIVATIVE; CILASTATIN PLUS IMIPENEM; CLONAZEPAM; CORTICOSTEROID; GLUCURONIDE; GYRASE INHIBITOR; MACROLIDE; METRONIDAZOLE; MORPHINE; PENICILLIN DERIVATIVE; PENICILLIN G; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLONE DERIVATIVE; SPIRONOLACTONE; TETRACYCLINE DERIVATIVE; TUBERCULOSTATIC AGENT; UNINDEXED DRUG;

BODY SURFACE; CHILD; CHILD DEVELOPMENT; CHILDHOOD DISEASE; COGNITIVE DEFECT; CORTICOSTEROID INDUCED OSTEOPOROSIS; DEVELOPMENTAL DISORDER; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG LEGISLATION; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG PROTEIN BINDING; GROWTH DISORDER; HUMAN; IMMATURITY; KIDNEY FAILURE; KIDNEY FUNCTION; MEDICAL SPECIALIST; MEDICATION ERROR; NEONATOLOGY; NEPHROLOGY; NEWBORN CARE; PATIENT CARE; PEDIATRICS; PRACTICE GUIDELINE; PREMATURITY; PRIORITY JOURNAL; REVIEW; TIME MANAGEMENT; TOOTH MALFORMATION;

CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INFORMATION SERVICES; GLOMERULAR FILTRATION RATE; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; KIDNEY FAILURE, CHRONIC; OUTCOME ASSESSMENT (HEALTH CARE); PHARMACEUTICAL PREPARATIONS; PRACTICE GUIDELINES;

EID: 28444435110     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-005-1922-9     Document Type: Review

References (44)

1. Rane A (1992) Drug disposition and action in infants and children. In: Yaffe SJ, Aranda JV (eds) Pediatric Pharmacology. WB Saunders, Philadelphia, pp 10-21
2. Port RE, Kiepe D, Van Guilder M, Jelliffe RW, Mehls O (2004) Recombinant human erythropoietin for the treatment of renal anaemia in children: No justification for bodyweight-adjusted dosage. Clin Pharmacokinet 43:57-70 14715051
3. Hyvärinen M, Zeltzer P, Oh W, Stiehm ER (1973) Influence of gestational age on serum levels of alpha-1 fetoprotein, IgG globulin, and albumin in newborn infants. J Pediatr 82:430-437 4121530
4. Wood M, Wood AJJ (1981) Changes in plasma drug binding and alpha-1-glycoprotein in mother and newborn infant. Clin Pharmacol Ther 29:522-566 7471620
5. Rane A, Lunde PK, Jalling B, Yaffe SJ, Sjöqvist F (1971) Plasma protein binding of diphenylhydantoin in normal and hyperbilirubinemic infants. J Pediatr 78:877-882 5104122
6. Dasgupta A, Crossey MJ (1997) Elevated free fatty acid concentrations in lipemic sera reduce protein binding of valproic acid significantly more than phenytoin. Am J Med Sci 313:75-79 10.1097/00000441-199702000-00001
7. Pacifici GM, Taddeucci-Brunelli G, Rane A (1984) Clonazepam serum protein binding during development. Clin Pharmacol Ther 35:354-359 6697643
8. Fawer CL, Torrado A, Guignard JP (1979) Maturation of renal function in full-term and premature neonates. Helv Paediatr Acta 34:11-21 429191
9. Stewart CF, Hampton EM (1987) Effect of maturation on drug disposition in pediatric patients. Clin Pharmacol 6:548-64
10. Lebenthal E, Lee PC, Heitlinger LA (1983) Impact of development of the gastrointestinal tract on infant feeding. J Pediatr 102:1-9 6401326
11. Del Olmo E, Pazos A (2001) Aminergic receptors during the development of the human brain: The contribution of in vitro imaging techniques. J Chem Neuroanatom 22:101-114
12. Mato S, Del Olmo E, Pazos A (2003) Ontogenetic development of cannabinoid receptor expression and signal transduction functionality in the human brain. Eur J Neurosci 17:1747-1754
13. Höcker B, John U, Plank C et al (2004) Successful withdrawal of steroids in pediatric renal transplant recipients receiving cyclosporine A and mycophenolate mofetil treatment: Results after four years. Transplantation 78:228-234
14. Fleming P, Witkop CJJ, Kuhlmann WH (1987) Staining and hypoplasia of enamel caused by tetracycline: Case report. Pediatr Dent 9:245-246
15. Greenglass EJ (1992) The adverse effects of cocaine on the developing human. In: Yaffe SJ, Aranda JV (eds) Pediatric pharmacology. WB Saunders, Philadelphia, pp 598-604
16. Pharmaceutical companies (1993) Drug information sheets
17. Yee CL, Duffy C, Gerbino PG, Stryker S, Noel GJ (2002) Tendon or joint disorders in children after treatment with fluoroquinolones or azithromycin. Pediatr Infect Dis J 21:525-529
18. Chauvin M, Sandouk P, Scherrmann JM et al (1987) Morphine pharmacokinetics in renal failure. Anesthesiology 66:327-331
19. Bennett WM (1981) Altering drug dose in patients with diseases of the kidney and liver. In: Anderson RJ, Schrier RW (eds) Clinical use of drugs in patients with kidney and liver disease. WB Saunders, Philadelphia, pp 16-29
20. Heymsfield SB, Arteaga C, McManus C, Smith J, Moffitt S (1983) Measurement of muscle mass in humans: Validity of the 24-hour urinary creatinine method. Am J Clin Nutr 37:478-494
21. Levey AS (1990) Measurement of renal function in chronic renal disease. Kidney Int 38:167-184
22. Trompeter RS (1987) A review of drug prescribing in children with end-stage renal failure. Pediatr Nephrol 1:183-194
23. Schaefer F, Klaus G, Müller-Wiefel DE, Mehls O, Mid European Pediatric Peritoneal Dialysis Study Group (MEPPS) (1999) Intermittent versus continuous intraperitoneal glycopeptide/ceftazidime treatment in children with peritoneal dialysis-associated peritonitis. J Am Soc Nephrol 10:136-145
24. Carmichael DHS (2005) Handling of drugs in kidney disease. In: Davison AM, Cameron JS, Grünfeld J-P et al (eds) Oxford textbook of clinical nephrology. Oxford University Press, Oxford, pp 2599-2618
25. Forth W, Henschler D, Rummel W (1988) Pharmakologie und Toxikologie. BI Wissenschaftsverlag, Mannheim
26. De Broe ME (2005) Drug-induced nephropathies. In: Davison AM, Cameron JS, Grünfeld J-P et al (eds) Oxford textbook of clinical nephrology. Oxford University Press, Oxford, pp 2581-2598
27. Gambertoglio JG, Lauer RM (1981) Use of neuropsychiatric drugs. In: Anderson RJ, Schrier RW (eds) Clinical use of drugs in patients with kidney and liver disease. WB Saunders, Philadelphia, pp 276-295
28. Sontheimer, D (1993) Dosierungen in der pädiatrischen Intensivtherapie. Dosage tables of the University Children's Hospital, Heidelberg
29. Milatovic D, Braveny I (1995) Praktische Hinweise zur antimikrobiellen Therapie und Diagnostik. MMW-Medizin Verlag, Munich
30. Daschner F (2002) Antibiotika am Krankenbett. Springer Verlag, Berlin, Heidelberg, New York
31. Rote L. Rote Liste (German Drug Index) (2003) Editio Cantor, Aulendorf, Germany
32. MicroMedex (1997) DrugKnowledge System (pharmacological database)
33. Adelman RD, Sinaiko AR (1987) Drugs and the kidney. In: Holliday MA, Barratt TM, Vernier RL (eds) Pediatric nephrology. Williams & Wilkins, Baltimore
34. Anderson RC, Gambertoglio JG, Schrier RW (1978) Clinical use of drugs in renal failure. CC Thomas Publisher, Springfield, IL
35. Bennett WM (1986) Prescribing drugs for patients with reduced renal function. In: Bennett WM (ed) Drugs and renal disease. Churchill Livingstone, Edinburgh, pp 26-65
36. Büchele W (1996) Arzneimitteldosierung bei Niereninsuffizienz. Janssen-Cilag Biotech, Neuss, Germany
37. Keller F (1997) Pharmakokinetik bei Niereninsuffizienz. In: Brass, Philipp, Schulz (eds) Manuale Nephrologicum. Dustri-Verlag, Munich
38. Müller-Wiefel DE (1989) Niere und Medikamente. In: Bachmann KD, Ewerbeck H, Kleihauer E, Russi E, Stalder G (eds) Pädiatrie in Praxis und Klinik. Georg Thieme Verlag, Stuttgart, pp 189-193
39. Seyffart G (1991) Drug dosage in renal insufficiency. Kluwer Academic Publishers, Boston
40. Weber LT, Shipkova M, Lamersdorf T et al (1998) Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. J Am Soc Nephrol 9:1511-1520
41. Keane WF, Alexander SR, Bailie GR et al (1996) Peritoneal dialysis-related peritonitis treatment recommendations: 1996 update. Perit Dial Int 16:557-573
42. Warady BA, Schaefer F, Holloway M et al (2000) Consensus guidelines for the treatment of peritonitis in pediatric patients receiving peritoneal dialysis. Perit Dial Int 10:610-624
43. Daschner M (2003) Tabellarium Nephrologicum. Shaker Verlag, Aachen
44. Daschner M, Cochat P (2002) Pharmakotherapie bei Niereninsuffizienz. In: Schärer K, Mehls O (eds) Pädiatrische Nephrologie. Springer Verlag, Berlin, Heidelberg, New York, pp 467-482